TRIM family contribute to tumorigenesis, cancer development, and drug resistance

Table 1 The expression levels of TRIM family proteins related to the adverse prognostic

Cancer type	Low expression level	High expression level
AML	TRIM62 [23]	/
HCC	TRIM26 [24], TRIM28, TRIM37, TRIM45, TRIM59 [25], TRIM59 [26]	TRIM11 [27, 28], TRIM16 [29], TRIM24 [30], TRIM25 [31], TRIM27 [32], TRIM31 [33], TRIM37 [34], TRIM50 [26], TRIM3, TRIM5, TRIM21, TRIM27, TRIM32, TRIM44, TRIM47, TRIM72 [35]
RCC	/	TRIM27 [36], TRIM37 [37], TRIM44 [38]
UCB	/	TRIM65 [39]
GBC		TRIM31 [40]
PTC	/	TRIM14 [41]
HEC	/	TRIM44 [42]
TGCT	/	TRIM44 [43]
NPC	/	TRIM11 [44]
OC	TRIM50 [45]	TRIM59 [46]
CRC	TRIM1, TRIM2, TRIM6, TRIM13, TRIM26, TRIM35,TRIM55 [47], TRIM58 [48]	TRIM23 [49], TRIM24 [50], TRIM27 [51], TRIM47 [47], TRIM39 [52]
Pancreatic carcinoma	TRIM36 [53], TRIM50 [54]	TRIM11 [55], TRIM15 [56], TRIM37 [57], TRIM47 [58], TRIM59 [59]
Gastric carcinoma	TRIM3 [60], TRIM21 [61]	TRIM14 [62], TRIM15 [63], TRIM23 [64], TRIM29 [65], TRIM32 [66, 67], TRIM44 [68], TRIM47 [69], TRIM54 [70]
Glioblastoma	TRIM8 [71], TRIM16 [72], TRIM17 [73]	TRIM14 [74], TRIM21 [75], TRIM28 [76]
Breast carcinoma	TRIM16 [72], TRIM29 [77], TRIM31 [78], TRIM35 [79]	TRIM3 [80], TRIM39 [81], TRIM44 [82, 83], TRIM47 [84], TRIM59 [85, 86], TRIM62 [87]
Lung carcinoma	TRIM28 [88], TRIMs56 [89]	TRIM11 [90], TRIM15 [91, 92], TRIM23 [93], TRIM35 [94], TRIM46 [95], TRIM66 [96]
melanoma	/	TRIM27 [97]
Squamous carcinoma	/	TRIM28 [98]
Osteosarcoma	TRIM22 [99]	TRIM7 [100]

The expression levels of different TRIM family proteins positively related to the adverse prognostic in various types of clinical tumor tissue samples. The adverse prognostic refers to the lower survivability of the diagnosis
AML: acute myelocytic leukemia, HCC: hepatocellular carcinoma, RCC renal cell carcinoma, UCB: urothelium carcinoma, PTC: papillary thyroid cancer, LC lung cancer, HEC: human esophageal cancer, LUAD lung adenocarcinoma, TGCT testicular germ cell tumors, NPC nasopharyngeal carcinoma; OC ovarian cancer, CRC colorectal cancer

ISSN: 2162-3619